Aclaris (NASDAQ: ACRS) CFO nets shares after RSU vesting

Q: How many Aclaris (ACRS) RSUs vested for the CFO in this Form 4?

22,025 restricted stock units vested for the Aclaris CFO. Each RSU represents a right to receive one share of common stock, so 22,025 RSUs became 22,025 shares of Aclaris Therapeutics common stock on February 3, 2026, at an exercise price of $0 per share.

Q: What is the vesting schedule for the Aclaris (ACRS) CFO’s RSUs?

The CFO’s RSUs vest over four years in equal installments. The shares underlying these restricted stock units vest on the first, second, third, and fourth anniversaries of February 3, 2025, contingent on the executive’s continuous service under the company’s equity plan.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Aclaris Therapeutics Chief Financial Officer Kevin Balthaser reported routine equity compensation activity. On February 3, 2026, 22,025 restricted stock units converted into an equal number of common shares at an exercise price of $0. To cover tax withholding on this vesting, 6,449 common shares were withheld by the company at $3.47 per share.

After these transactions, Balthaser directly owned 185,755 shares of common stock and 66,075 restricted stock units, which continue to vest in four equal annual installments starting from February 3, 2025, contingent on his continued service.

Insider Trade Summary

22,025 shares exercised/converted

Mixed 3 txns

Insider Balthaser Kevin

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	22,025	$0.00	--
Exercise	Common Stock	22,025	$0.00	--
Tax Withholding	Common Stock	6,449	$3.47	$22K

Holdings After Transaction: Restricted Stock Units — 66,075 shares (Direct); Common Stock — 192,204 shares (Direct)

Footnotes (1)

Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

Form 4 Insider Transactions: What Each Field Means →

02/05/2026 - 04:41 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Balthaser Kevin

(Last)

(First)

(Middle)

C/O ACLARIS THERAPEUTICS, INC.

701 LEE ROAD, SUITE 103

(Street)

WAYNE

19087

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Aclaris Therapeutics, Inc. [ ACRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/03/2026		M		22,025	A	⁽¹⁾	192,204	D
Common Stock	02/03/2026		F⁽²⁾		6,449	D	$3.47	185,755	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	02/03/2026		M			22,025	⁽³⁾	⁽³⁾	Common Stock	22,025	$0	66,075	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

2. The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.

3. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

	/s/ Matthew Rothman, Attorney-in-Fact	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Aclaris Therapeutics (ACRS) report for its CFO?

Aclaris Therapeutics reported routine equity compensation activity for CFO Kevin Balthaser. On February 3, 2026, 22,025 restricted stock units converted into common shares, and 6,449 shares were withheld by the company to satisfy tax obligations linked to the vesting event.

How many Aclaris (ACRS) RSUs vested for the CFO in this Form 4?

22,025 restricted stock units vested for the Aclaris CFO. Each RSU represents a right to receive one share of common stock, so 22,025 RSUs became 22,025 shares of Aclaris Therapeutics common stock on February 3, 2026, at an exercise price of $0 per share.

Why were 6,449 Aclaris (ACRS) shares withheld in the CFO’s Form 4?

6,449 shares were withheld to cover tax withholding obligations. The company retained these Aclaris common shares at $3.47 per share in connection with the vesting and settlement of the CFO’s restricted stock units reported in the Form 4 filing.

How many Aclaris Therapeutics (ACRS) shares does the CFO own after this transaction?

After the reported transactions, the CFO beneficially owned 185,755 common shares. This figure reflects the RSU conversion and the share withholding for taxes on February 3, 2026, and is reported as directly owned common stock in the filing.

How many Aclaris (ACRS) restricted stock units does the CFO still hold?

The CFO holds 66,075 restricted stock units after the transaction. These RSUs are scheduled to vest in four equal installments on the first through fourth anniversaries of February 3, 2025, assuming the executive maintains continuous service with Aclaris Therapeutics.

What is the vesting schedule for the Aclaris (ACRS) CFO’s RSUs?

The CFO’s RSUs vest over four years in equal installments. The shares underlying these restricted stock units vest on the first, second, third, and fourth anniversaries of February 3, 2025, contingent on the executive’s continuous service under the company’s equity plan.